Showing results (281-290 of 320) with videos related to

Sort By:
Pageof 32
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 1, 1988
Phase I trial of a mouse monoclonal antibody against GD3 ganglioside in patients with melanoma: induction of inflammatory responses at tumor sitesS Vadhan-Raj, C Cordon-Cardo, E Carswell, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 1, 1990
A phase I toxicity, pharmacology, and dosimetry trial of monoclonal antibody OKB7 in patients with non-Hodgkin's lymphoma: effects of tumor burden and antigen expressionD A Scheinberg, D J Straus, S D Yeh, et al.
Proceedings of the National Academy of Sciences of the United States of America|July 22, 1997
Characterization of tumor necrosis factor-deficient miceM W Marino, A Dunn, D Grail, et al.
Proceedings of the National Academy of Sciences of the United States of America|June 1, 1987
Monoclonal antibody to an intracellular antigen images human melanoma transplants in nu/nu miceS Welt, M J Mattes, R Grando, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 1, 1993
Phase I dose-escalation trial of iodine 131-labeled monoclonal antibody OKB7 in patients with non-Hodgkin's lymphomaM S Czuczman, D J Straus, C R Divgi, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 1, 1994
Antibody targeting in metastatic colon cancer: a phase I study of monoclonal antibody F19 against a cell-surface protein of reactive tumor stromal fibroblastsS Welt, C R Divgi, A M Scott, et al.
Biochimica Et Biophysica Acta|April 21, 1999
Isoforms of the human PDZ-73 protein exhibit differential tissue expressionM J Scanlan, B Williamson, A Jungbluth, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 1, 1993
Dose-escalation trial of M195 labeled with iodine 131 for cytoreduction and marrow ablation in relapsed or refractory myeloid leukemiasM A Schwartz, D R Lovett, A Redner, et al.
Pageof 32